[Form 4] BIOXYTRAN, INC Insider Trading Activity

Rhea-AI Filing Summary

Bioxytran, Inc. (BIXT) reported an insider equity transaction by a director on a Form 4. On 11/14/2025, the director acquired 38,588 preferred shares at a price of $0.35 per share. Following this transaction, the director beneficially owned 372,580 shares, held as a direct ownership position. The filing was made by a single reporting person in the capacity of director, and no derivative securities transactions were reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Utter Anders

(Last) (First) (Middle)

BIOXYTRAN, INC

233 NEEDHAM ST., SUITE 300

(Street)

NEWTON MA 02464

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOXYTRAN, INC [ BIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
preferred	11/14/2025		A		38,588	A	$0.35	372,580	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Anders Utter	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bioxytran (BIXT) disclose on this Form 4?

The filing shows a director of Bioxytran, Inc. acquired 38,588 preferred shares at $0.35 per share on 11/14/2025.

How many Bioxytran (BIXT) shares does the director own after the reported trade?

After the transaction, the director beneficially owned 372,580 shares of Bioxytran, Inc., reported as direct ownership.

What is the role of the reporting person in Bioxytran (BIXT)?

The reporting person is identified as a director of Bioxytran, Inc., with the Form 4 indicating a filing by one reporting person.

What was the transaction date on the Bioxytran (BIXT) Form 4?

The earliest transaction date reported is 11/14/2025, when the director acquired the preferred shares.

Were any derivative securities reported for Bioxytran (BIXT) in this Form 4?

No. Table II for derivative securities shows no transactions reported for options, warrants, or other derivative instruments.

Is this Bioxytran (BIXT) Form 4 filed by an individual or a group?

The Form 4 indicates it is filed by one reporting person, not by more than one reporting person.